Atypical haemolytic uremic syndrome: when multiple etiologies meet

[1]  A. Asif,et al.  The potential role of complements in cocaine-induced thrombotic microangiopathy , 2017, Clinical kidney journal.

[2]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[3]  Le Ma,et al.  Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome , 2016, International journal of environmental research and public health.

[4]  R. Torra,et al.  Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento: Documento de consenso , 2015 .

[5]  S. Rodríguez de Córdoba,et al.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[6]  C. Skerka,et al.  Complement factor H related proteins (CFHRs). , 2013, Molecular immunology.

[7]  H. Cordell,et al.  Determining the Population Frequency of the CFHR3/CFHR1 Deletion at 1q32 , 2013, PloS one.

[8]  A. Bagga,et al.  Peripheral Gangrene in Children With Atypical Hemolytic Uremic Syndrome , 2013, Pediatrics.

[9]  P. Barlow,et al.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. , 2010, Blood.

[10]  M. López-Trascasa,et al.  Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. , 2009, Blood.

[11]  P. Zipfel,et al.  Autoantibodies in haemolytic uraemic syndrome (HUS) , 2009, Thrombosis and Haemostasis.